ThermoChem HT-2000 System and Intraperitoneal Hyperthermia (IPH) Procedure Kit (HT-2000)

K240447 · Thermasolutions, LLC · MLW · May 5, 2025 · Gastroenterology, Urology

Device Facts

Record IDK240447
Device NameThermoChem HT-2000 System and Intraperitoneal Hyperthermia (IPH) Procedure Kit (HT-2000)
ApplicantThermasolutions, LLC
Product CodeMLW · Gastroenterology, Urology
Decision DateMay 5, 2025
DecisionSESK
Submission TypeTraditional
Regulation21 CFR 876.5630
Device ClassClass 2
AttributesTherapeutic

Indications for Use

The intended use of the ThermoChem HT-2000 System is to raise the core temperature of the peritoneum to a desired target temperature, in patients who require warming, including oncology patients, by continuously lavaging with circulated and warmed Lactated Ringer's Solution, U.S.P., or other physician specified fluids.

Device Story

ThermoChem HT-2000 System consists of reusable ThermoChem unit with touchscreen monitor and single-use sterile Intraperitoneal Hyperthermia (IPH) Procedure Kit. Device functions by heating and circulating sterile fluids (e.g., Lactated Ringer's Solution) to raise peritoneal core temperature to physician-selected target. Operated by clinicians in clinical settings for therapies such as continuous hyperthermic peritoneal perfusion. Touchscreen interface allows user control of system functions. Output is warmed, circulating fluid lavage; clinical decision-making relies on physician selection of fluids and therapy parameters. Benefits include controlled temperature-targeted warming of peritoneum for oncology patients.

Clinical Evidence

No clinical performance testing was conducted. Substantial equivalence is supported by bench testing data from the predicate device (K131583).

Technological Characteristics

System comprises reusable unit with touchscreen monitor and single-use disposable IPH kit. Operates via fluid heating and circulation. No changes in materials, design, or energy source compared to predicate. Software interface provides user control.

Indications for Use

Indicated for patients requiring peritoneal warming, including oncology patients, via continuous lavage with warmed Lactated Ringer's Solution or other physician-specified fluids.

Regulatory Classification

Identification

(1) A peritoneal dialysis system and accessories is a device that is used as an artificial kidney system for the treatment of patients with renal failure or toxemic conditions, and that consists of a peritoneal access device, an administration set for peritoneal dialysis, a source of dialysate, and, in some cases, a water purification mechanism. After the dialysate is instilled into the patient's peritoneal cavity, it is allowed to dwell there so that undesirable substances from the patient's blood pass through the lining membrane of the peritoneal cavity into this dialysate. These substances are then removed when the dialysate is drained from the patient. The peritoneal dialysis system may regulate and monitor the dialysate temperature, volume, and delivery rate together with the time course of each cycle of filling, dwell time, and draining of the peritoneal cavity or manual controls may be used. This generic device includes the semiautomatic and the automatic peritoneal delivery system.(2) The peritoneal access device is a flexible tube that is implanted through the abdominal wall into the peritoneal cavity and that may have attached cuffs to provide anchoring and a skin seal. The device is either a single use peritioneal catheter, intended to remain in the peritoneal cavity for less than 30 days, or a long term peritoneal catheter. Accessories include stylets and trocars to aid in the insertion of the catheter and an obturator to maintain the patency of the surgical fistula in the abdominal wall between treatments. (3) The disposable administration set for peritoneal dialysis consists of tubing, an optional reservoir bag, and appropriate connectors. It may include a peritoneal dialysate filter to trap and remove contaminating particles. (4) The source of dialysate may be sterile prepackaged dialysate (for semiautomatic peritoneal dialysate delivery systems or “cycler systems”) or dialysate prepared from dialysate concentrate and sterile purified water (for automatic peritoneal dialysate delivery systems or “reverse osmosis” systems). Prepackaged dialysate intended for use with either of the peritoneal dialysate delivery systems is regulated by FDA as a drug.

Special Controls

*Classification.* Class II (special controls). The following accessories are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9: A catheter finger grip that is non-patient contacting and intended for single use with a peritoneal catheter; a continuous ambulatory peritoneal dialysis (CAPD) belt; and a catheter stand that does not include weigh scales.

Predicate Devices

Submission Summary (Full Text)

{0} [LOGO] FDA U.S. FOOD & DRUG ADMINISTRATION May 5, 2025 ThermaSolutions, LLC % Jessica Czamanski Regulatory, Quality & Compliance Consultant DuVal & Associates, P.A. Suite 1820, Medical Arts Building 825 Nicollet Mall Minneapolis, Minnesota 55402 Re: K240447 Trade/Device Name: ThermoChem HT-2000 System and Intraperitoneal Hyperthermia (IPH) Procedure Kit (HT-2000) Regulation Number: 21 CFR 876.5630 Regulation Name: Peritoneal dialysis system and accessories Regulatory Class: Class II Product Code: MLW Dated: March 5, 2025 Received: March 6, 2025 Dear Jessica Czamanski: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. However, you are responsible to determine that the medical devices you use as components in the kit have either been determined as substantially equivalent under the premarket notification process (Section 510(k) of the act), or were legally on the market prior to May 28, 1976, the enactment date of the Medical Device Amendments. Please note: If you purchase your device components in bulk (i.e., unfinished) and further process (e.g., sterilize) you must submit a new 510(k) before including these components in your kit/tray. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {1} K240447 - Jessica Czamanski Page 2 If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical- {2} K240447 - Jessica Czamanski Page 3 devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, Maura Rooney -S Maura Rooney Assistant Director DHT3A: Division of Renal, Gastrointestinal, Obesity, and Transplant Devices OHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3} DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration # Indications for Use Form Approved: OMB No. 0910-0120 Expiration Date: 07/31/2026 See PRA Statement below. Submission Number (if known) K240447 Device Name ThermoChem HT-2000 System and Intraperitoneal Hyperthermia (IPH) Procedure Kit (HT-2000) Indications for Use (Describe) The intended use of the ThermoChem HT-2000 System is to raise the core temperature of the peritoneum to a desired target temperature, in patients who require warming, including oncology patients, by continuously lavaging with circulated and warmed Lactated Ringer's Solution, U.S.P., or other physician specified fluids. Type of Use (Select one or both, as applicable) ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) # CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {4} **DUVAL & ASSOCIATES** Drug, Device and Food Law 1820 Medical Arts Building 825 Nicollet Mall Minneapolis, MN 55402 612-338-7170 Main # **K240447 – 510(k) Summary** # **I. Submitter** Submitter Name: ThermaSolutions LLC Contact Person: Rhea Johny Regulatory Specialist Address: 1889 Buerkle Road White Bear Lake MN 55110 United States Telephone: (651) 374-9728 Email: rjohny@thermasolutions.com Date of Preparation: May 5th, 2025 # **II. Application Correspondent** Contact's Name: DuVal & Associates, P. A. Contact Person: Jessica Czamanski Address: Medical Arts Building 825 Nicollet Mall Suite 1820 Minneapolis MN 55402 United States Telephone: (754) 422-9101 Email: jczamanski@duvalfdalaw.com # **III. Device** Trade Name: ThermoChem HT-2000 System and Intraperitoneal Hyperthermia (IPH) Procedure Kit (HT-2000) Common Name: Peritoneal dialysis system and accessories Classification Name: Warmer, Peritoneal Dialysate Product Classification: Class II Regulation Number: 21 CFR 876.5630 Product Code: MLW # **IV. Predicate Device** Manufacturer: ThermaSolutions LLC Device Name: ThermoChem HT-2000 *Drug, Device and Food Law* Page 1 of 3 {5} DUVAL & ASSOCIATES Drug, Device and Food Law 1820 Medical Arts Building 825 Nicollet Mall Minneapolis, MN 55402 612-338-7170 Main 510(k) Number: K131583 Product Classification: Class II Regulation Number: 21 CFR 876.5630 Product Code: MLW # V. Device Description The ThermoChem HT-2000 System is composed of the ThermoChem Unit and touchscreen monitor, and the Intraperitoneal Hyperthermia (IPH) Procedure Kit. The ThermoChem HT-2000 and IPH Procedure pack are used to raise the core temperature of the peritoneum to a desired target temperature by continuously lavaging the peritoneum with circulating and warmed sterile solution. The ThermoChem unit and monitor are reusable components of the system. The IPH Procedure kit consists of an array of sterile, single-use, disposable components. The touchscreen monitor on the ThermoChem unit provides for the user interface with the ThermoChem system. The touch screen can be used to control the main functions of the system. The ThermoChem HT-2000 System is comprised of the same hardware as the predicate K31583 device. The ThermoChem HT-2000 is a tool for the heating and circulation of fluid. Physicians are responsible for selecting the fluids used and the therapy delivered. Oncology patients, undergoing a temperature-targeted warming of the peritoneum with continuous circulation and lavage, may be subject to physician specified fluids for therapies such as continuous hyperthermic peritoneal perfusion. There are no known drugs, other than Lactated Ringer's Solution, U.S.P., specifically approved for these therapies. # VI. Intended Use/Indications for Use The intended use of the ThermoChem HT-2000 System is to raise the core temperature of the peritoneum to a desired target temperature, in patients who require warming, including oncology patients, by continuously lavaging with circulated and warmed Lactated Ringer's Solution, U.S.P., or other physician specified fluids. # VII. Indications for Use Comparison The proposed indications for use clarify that the patient population includes oncology patients and that the clinical has the responsibility to specify which fluids other than Lactated Ringer's should be used with the device, adding specificity to the indications for use under the device's general intended use. # VIII. Comparison of Technological Characteristics The subject ThermoChem System has not undergone any significant changes in materials, design, energy source, or other features compared to the K131583 clearance. The only change that is the Drug, Device and Food Law Page 2 of 3 {6} **DUVAL & ASSOCIATES** Drug, Device and Food Law 1820 Medical Arts Building 825 Nicollet Mall Minneapolis, MN 55402 612-338-7170 Main subject of this 510(k) is the indication for use change which does not result in a change to the previously cleared intended use. # **IX. Performance Testing – Bench** All performance data included in K131583 for the predicate ThermoChem HT-2000, also supports the proposed device. # **Performance Testing – Animal** This submission does not include any animal performance testing. It was determined that no such testing is required to demonstrate substantial equivalence. # **Performance Testing – Clinical** This submission does not include any clinical performance testing. It was determined that no such testing is required to demonstrate substantial equivalence. # **X. Conclusion** The proposed ThermoChem HT-2000 has the same intended use, operating principle, fundamental technology, materials, and manufacturing as the predicate device. The difference in indications for use, clarifies the patient population for which the device is intended which is the same population that the predicate device has been used on since its clearance. These differences in indications for use do not introduce new questions for safety and effectiveness. The information provided in this submission demonstrated that the subject device, ThermoChem HT-2000, is substantially equivalent to its predicate, ThermoChem HT-2000 K131583. ---*Drug, Device and Food Law* Page 3 of 3
Innolitics
Guidance Recalls

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...